A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study also hitting an enrollment target, triggering a $200 milestone payment due ...

The last time I wrote about Dyne Therapeutics (DYN) it was with respect to a Seeking Alpha article entitled "Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker". With ...

– 53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing – – PGN-EDODM1 was generally well-tolerated at 15 mg/kg, ...

Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical ...

BOSTON, February 24, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming ...

“Why you can trust Digital Trends – We have a 20-year history of testing, reviewing, and rating products, services and apps to help you make a sound buying decision. Find out more about how we test ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Editors' Note: We updated this review on Dec. 20 to mention the special price for this tested configuration available via Costco. Last year's review put the Intel-powered 2022 HP Pavilion Plus 14 near ...

HP's Pavilion Desktop line (starts at $549; $757 as tested) is a familiar sight at big-box retailers for a reason—it gets most things right. This family-friendly budget desktop has the performance to ...